The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...
NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.1 billion market cap biopharmaceutical company with impressive 91% gross profit margins, has reached a settlement agreement with Teva ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...
Many people use the terms ‘migraine’ and ‘headache’ interchangeably. This leads many people to believe that migraines are not ...